Biology:Epoxygenase

From HandWiki
Short description: Set of cytochrome P450 enzymes

Epoxygenases are a set of membrane-bound, heme-containing cytochrome P450 (CYP P450 or just CYP) enzymes that metabolize polyunsaturated fatty acids to epoxide products that have a range of biological activities.[1] The most thoroughly studied substrate of the CYP epoxylgenases is arachidonic acid. This polyunsaturated fatty acid is metabolized by cyclooxygenases to various prostaglandin, thromboxane, and prostacyclin metabolites in what has been termed the first pathway of eicosanoid production; it is also metabolized by various lipoxygenases to hydroxyeicosatetraenoic acids (e.g. 5-Hydroxyeicosatetraenoic acid, 12-Hydroxyeicosatetraenoic acid, 15-hydroxyicosatetraenoic acid) and leukotrienes (e.g. leukotriene B4, leukotriene C4) in what has been termed the second pathway of eicosanoid production. The metabolism of arachidonic acid to epoxyeicosatrienoic acids by the CYP epoxygenases has been termed the third pathway of eicosanoid metabolism.[2] Like the first two pathways of eicosanoid production, this third pathway acts as a signaling pathway wherein a set of enzymes (the epoxygenases) metabolize arachidonic acid to a set of products (the eicosatrienoic acid epoxides, abbreviated as EETs, which are classified as nonclassic eicosanoids) that act as secondary signals to work in activating their parent or nearby cells and thereby orchestrate functional responses. However, none of these three pathways is limited to metabolizing arachidonic acid to eicosanoids. Rather, they also metabolize other polyunsaturated fatty acids to products that are structurally analogous to the eicosanoids but often have different bioactivity profiles. This is particularly true for the CYP epoxygenases which in general act on a broader range of polyunsaturated fatty acids to form a broader range of metabolites than the first and second pathways of eicosanoid production. Furthermore, the latter pathways form metabolites many of which act on cells by binding with and thereby activating specific and well-characterized receptor proteins; no such receptors have been fully characterized for the epoxide metabolites. Finally, there are relatively few metabolite-forming lipoxygenases and cyclooxygenases in the first and second pathways and these oxygenase enzymes share similarity between humans and other mammalian animal models. The third pathway consists of a large number of metabolite-forming CYP epoxygenases and the human epoxygenases have important differences from those of animal models. Partly because of these differences, it has been difficult to define clear roles for the epoxygenase-epoxide pathways in human physiology and pathology.

CYP epoxygenases

The cytochrome P450 (CYP) superfamily of membrane-bound (typically endoplasmic reticulum-bound) enzymes contain a heme cofactor and therefore are hemoproteins. The superfamily comprises more than 11,000 genes categorized into 1,000 families that are distributed broadly throughout bacteria, archaea, fungi, plants, animals, and even viruses (see Cytochrome P450). The CYP enzymes metabolize an enormously large variety of small and large molecules including foreign chemical substances, i.e. xenobiotics and pharmaceuticals, as well as a diversity of endogenously formed substances such as various steroids, vitamin D, bilirubin, cholesterol, and fatty acids.[2] Humans have 57 putatively active CYP genes and 58 CYP pseudogenes of which only a few are polyunsaturated fatty acid (PUFA) epoxygenases, i.e. enzymes with the capacity to attach atomic oxygen (see Allotropes of oxygen) to the carbon-carbon double bonds of long chain PUFA to form their corresponding epoxides.[2] These CYP epoxygenases represent a family of enzymes that consists of several members of the CYP1 and CYP2 subfamilies. The metabolism of the straight chain 20-carbon polyunsaturated fatty eicosatetraenoic acid, arachidonic acid, by certain CYP epoxygenases is a good example of their action. Arachidonic acid has 4 cis-configured double bonds (see Cis–trans isomerism) located between carbons 5-6, 8-9, 11-12, and 14-15 Double bonds. (The cis configuration is termed Z in the IUPAC Chemical nomenclature used here.). It is therefore 5Z,8Z,11Z,14Z-eicosatetraenoic acid. Certain CYP epoxygenases attack these double bounds to form their respective eicosatrienoic acid epoxide regioisomers (see Structural isomer, section on position isomerism [regioisomerism]). The products are therefore 5,6-EET (i.e. 5,6-epoxy-8Z,11Z,14Z-eicosatetraenoic acid), 8,9-EET (i.e. 5,6-epoxy-8Z,11Z,14Z-eicosatetraenoic acid), 11,12-EET (i.e. 11,12-epoxy-5Z,8Z,14Z-eicosatetraenoic acid), and/or 14,15-EET (i.e. 14,15-epoxy-5Z,8Z,11Z-eicosatetraenoic acid, the structure of which is illustrated in the attached figure). Note that the eicosatetraenoate substrate loses one double bound to become an eicosatrienoic acid with three double bonds and that the epoxygenases typically form a mixture of R/S enantiomers at the attacked double bound position. Thus, the CYP epoxygenases which attack arachidonic acid's double bound between carbon 14 and 15 form a mixture of 14R,15S-ETE and 14S,15R-ETE.[1] However, each CYP epoxygenase often shows preferences in the position of the double bound on which they act, partial selectivity in the R/S enantiomer ratios that they make at each double bound position, and different double bond position preferences and R/S selectivity ratios with different PUFA substrates.[3] Finally, the product epoxides are short-lived in cells, generally existing for only several seconds before being converted by a Soluble epoxide hydrolase (also termed epoxide hydrolase 2 or sEH) to their corresponding dihydroxy-eicosatetraenoic acid (diHETE) products, e.g. 14,15-HETE rapidly becomes a mixture of 14(S),15(R)-diHETE and 14(R),15(S)-diHETE.[1] Although there are exceptions, the diHETE products are generally far less active than their epoxide precursors; the sEH pathway is therefore regarded as an inactivating pathway which functions to limit epoxide activity.[1][4]

The catalytic activity of endoplasmic reticulum-bound cytochrome P450 enzymes, including the epoxygenases, depends upon Cytochrome P450 reductase (POR); it transfers electrons to, and thereby regenerates the activity of, the CYPs.[2] The human gene that expresses POR is highly polymorphic (see Gene polymorphism); many of the polymorphic variant PORs cause significantly decreases or increases in the activity of the CYPs, including the epoxygenases.[2][5]

Scores of drugs have been shown to either inhibit or induce one or more of the CYP epoxygenases;[2]

CYP epoxygenase substrates and products

The most studied substrate of the CYP epoxygenases is the omega-6 fatty acid, arachidonic acid. However, the CYP epoxygenases also metabolize other omega-6 fatty acids such as linoleic acid and the omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid. The distinction between the omega-6 and omega-3 fatty acid substrates is important because omega-3 fatty acids metabolites can have lesser or different activities than omega-6 fatty acid metabolites; furthermore, they compete with the omega-6 fatty acids for the CYP epoxygenases thereby reducing the production of omega-6 fatty acid metabolites.[1][6] The human CYP P450 enzymes identified to have epoxygenase activity on one or more PUFA include CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP2J2, CYP2S1, CYP3A4, CYP4F2, CYP4F3A, CYP4F3B, CYP4A11, CYP4F8, and CYP4F12.[3][7][8][9] CYP2C8 and CYP2C9 form particularly large amounts of superoxide anion (chemical formula O−2) during their metabolism of polyunsaturated fatty acids; this reactive oxygen species is toxic to cells and may be responsible for some of the activities ascribed to the epoxides made by the two CYPs.[10]

Omega-6 fatty acids

Arachidonic acid

In humans, CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP2J2, and CYP2S1 isoforms metabolize arachidonic acid to Epoxyeicosatrienoic acids (i.e., EETs) as defined using recombinant CYPs in an In vitro microsome assay.[2][1][6][8][10] CYP2C9, and CYP2J2 appear to be the main producers of the EETs in humans with CYPP2C9 being the main unsaturated fatty acid epoxide producer in vascular endothelial cells and CYP2J2 being highly expressed (although less catalytically active than CYP2C9) particularly in heart muscle but also in kidneys, pancreas, lung, and brain; CYP2C8, CYP2C19, CYP2J2 are also implicated in converting arachidonic acid to epoxides in humans.[11] Most of these CYPs preferentially form 14,15-ETE, somewhat lower levels of 11,12-EET, and far lower, trace, or undetectable levels of 8,9-ETE and 4,5-ETE. There are exceptions to this rule with, for example, CYPE1 forming 14,15-EET almost exclusively, CYP2C19 forming 8,9-EET at slightly higher levels than 14,15-EET, and CYP3A4 forming 11,12-EET at slightly higher levels than 14,15-ETE.[1][11] 14,15-EET and 11,12-EET are the major EETs produced by mammalian, including human, tissues.[1] CYP2C9, CYP2JP, and possibly the more recently characterized CYP2S1 appear to be the main produces of the EETs in humans with CYPP2C9 being the main EET producer in vascular endothelial cells and CYP2JP being highly expressed (although less catalytically active than CYP2C) in heart muscle, kidneys, pancreas, lung, and brain.[11] CYP2S1 is expressed in macrophages, liver, lung, intestine, and spleen and is abundant in human and mouse atherosclerosis (i.e. Atheroma) plaques as well as inflamed tonsils.[10] CYP2S1 is expressed in macrophages, liver, lung, intestine, and spleen; is abundant in human and mouse atherosclerosis (i.e. Atheroma) plaques as well as inflamed tonsils; and, in addition to forming epoxides of arachidonic acid (and other polyunsaturated fatty acids), CYP2S1 metabolizes prostaglandin G2 and Prostaglandin H2 to 12-Hydroxyheptadecatrienoic acid. Possibly because of metabolizing and thereby inactivating the prostaglandins and/or because forming the bioactive metabolite, 12-hyddroxyheptadecatrienoic acid, rather than EETs, CYP2S1 may act to inhibit the function of monocytes and thereby limit inflammation as well as other immune responses.[8][10] The activities and clinical significance of the EETs are given on the epoxyeicosatrienoic acid page.

Linoleic acid

CYP2C9 and CYP2S1 are known to, and many or all of the other CYPs that act on arachidonic acid are thought to, metabolize the 18 carbon essential fatty acid, 9(Z),12(Z)-octadecadienoic acid, i.e. linoleic acid, at is 12,13 carbon-carbon double bout to form (+) and (-) epoxy optical isomers viz., the 12S,13R-epoxy-9(Z)-octadecenoic and 12R,13S-epoxy-9(Z)-octadecenoic acids; this set of optical isomers is also termed vernolic acid, linoleic acid 12:13-oxide, and leukotoxin. CYPC2C9 is known and the other arachidonic acid-metabolizing CYPs are thought to likewise attack linoleic acid at its 9,10 carbon-carbon double bound to form 9S,10R-epoxy-12(Z)-octadecenoic and 9R,10S-epoxy-12(Z)-octadecenoic acid optical isomers; this set of optical isomers is also termed coronaric acid, linoleic acid 9,10-oxide, and isoleukotoxin[1][12][13] These linoleic acid-derived leukotoxin and isoleukotoxin sets of optical isomers possess activities similar to those of other molecules called leukotoxins, such as the pore-forming leukotoxin family of RTX toxin virulence factor proteins secreted by gram-negative bacteria, e.g. Aggregatibacter actinomycetemcomitans and E. coli. That is, they are toxic to leukocytes as well as many other cell types and when injected into rodents produce multiple organ failure and respiratory distress.[1][14][15][16] These effects appear due to the conversion of leukotoxin to its dihydroxy counterparts, 9S,10R- and 9R,10S-dihydroxy-12(Z)-octadecenoic acids, and isoleukotoxin to its 12R,13S- and 12S,13R-dihydroxy-9(Z)-octadecenoic acid counterparts by soluble epoxide hydrolase.[17] Some studies suggest but have not proven that leukotoxin and isoleukotoxin, acting primarily if not exclusively through their respective dihydroxy counterparts, are responsible for or contribute to multiple organ failure, respiratory distress, and certain other cataclysmic diseases in humans.[15][18][19]

Adrenic acid

Adrenic acid or 7(Z),10(Z),13(Z),16(Z)-docosatetraenoic acid, an abundant fatty acid in the adrenal gland, kidney, vasculature, and early human brain, is metabolized primarily to 7(Z),10(Z),13(Z)-16,17-epoxy-docosatrienoic acid and smaller amounts of its 7,8-, 10,11-, and 13,14-epoxide-docosatrienoic acids by bovine coronary arteries and adrenal zona glomerulosa cells through the apparent action of an unidentified CYP epoxygenase(s); the eSH-dependent metabolism of these eoxide, 7,8-, 10,11-, and 13,14-dihydroxy-docosatrienoic acids relaxes pre-contracted coronary and adrenal gland arteries suggesting that the dihydroxy metabolites may act as vascular endothelium-derived Endothelium-derived relaxing factors.[20]

Omega-3 fatty acids

Eicosapentaenoic acid

5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA) is metabolized by the same CYP epoxygenases that metabolize arachidonic acid primarily to 17,18-epoxy-5(Z),8(Z),11(Z),14(Z)-eicosatetranoic acid and usually far smaller or undetectable amounts of EPA's 5,6-, 8,9-, 11,12-, or 14,15-epoxides; however, CYP2C9 metabolizes EPA primarily to 14,15-epoxy-5(Z),8(Z),11(Z),17(Z)-eicosatetranoic acid, CYP2C11 forms appreciable amounts of this 14,15-epoxide in addition to the 17,18-epoxide, and CYP2C18 forms appreciable amounts of the 11,12 epoxide (11,12-epoxy-5(Z),8(Z),14(Z),17(Z)-eicosatetranoic acid) in addition to the 17,18-epoxide. Furthermore, CYP4A11, CYP4F8, and CYP4F12, which are CYP monooxygenase rather than CYP epoxygeanse in that they metabolize arachidonic acid to monohydroxy eicosatetraenoic acid products (see 20-Hydroxyeicosatetraenoic acid), i.e. 19-hydroxy- and/or 18-hydroxy-eicosatetranoic acids, takes on epoxygenase activity in converting EPA primarily to its 17,18-epoxy metabolite (see epoxyeicosatetraenoic acid).[7]

Docosahexaenoic acid

4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-docosahexaenoic acid (DHA) is metabolized by the same CYP epoxygenases that metabolize arachidonic acid to form epoxide-containing docosapentaenoic acid products, particularly 19,20-epoxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentenoic acid.[21] These docosapentaenoic acid epoxides or Epoxydocosapentaenoic acids (EDPs) have a somewhat different set of activities than, and thereby may serve in part as counterpoises to, the EET's; EDPs may also be responsible for some the beneficial effects attributed to omega-6 fatty acid-rich foods such as fish oil (see Epoxydocosapentaenoic acid).[22]

α-Linolenic acid

The 18 carbon essential fatty acid, 9 α-Linolenic acid or 9(Z),12(Z),15(Z)-octadecatrienoic acid, is metabolized primarily to 9(Z),12(Z)-15,16-epoxy-octadecadienoic acid but also to smaller amounts of its 8,10- and 12,13-epoxides in the serum, liver, lung, and spleen of mice treated with a drug that increases the expression of CYP1A1, CYP1A2 and/or CYP1B1.[20][23] These epoxides are also found in the plasma of humans and their levels greatly increase in subjects given an α-linolenic acid-rich diet.[24]

Genetic polymorphism in CYP epoxygenases

Human CYP epoxygenase genes come in many single nucleotide polymorphism (SNP) variants some of which code for epoxygenase products with altered activity. Investigation into the impact of these variants on the bearers' health (i.e. phenotype) is an invaluable area of research which offers the opportunity to define the function of the epoxygenases and their polyunsaturated fatty acid metabolites in humans. However, SNP variants that cause altered polyunsaturated fatty acid metabolism may also cause altered metabolism of their other substrates, i.e. diverse xenobiotic (e.g. NSAID) and endotiotic (e.g. the primary female sex hormone, estradiol) compounds: the latter effects may lead to clinical manifestations that overshadow any manifestations resulting from changes in polyunsaturated fatty acid metabolism.

The most common SNP epoxygenase variants are as follows. 1) CYP2C8*3 (30411A>G, rs10509681,[25][unreliable source?] Lys399Arg) converts arachidonic acid to 11,12-EET and 14,15-EET with a turnover rate less than half that of wild type CYP2C8; in a single recent report, male but not female carriers of the CYP2C8*3 allele had an increased risk of essential hypertension.[26] Bearers of this SNP may[27] or may not[28] show increased risk of developing acute gastrointestinal bleeding during the use of non-steroidal anti-inflammatory drugs (NSAIDs) that are its substrates such as aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam, and valdecoxib. 2) CYP2J2*7 (−76G>T, rs890293,[29][unreliable source?] upstream Promoter (genetics) site) has decreased binding of the Sp1 transcription factor resulting in its lowered expressionas and lowered levels of EETs in plasma. Carriers of this SNP among a Uyghur population in China had a higher risk of coronary artery disease.[29][unreliable source?] However, CYP2J2*7 carriers showed no association with hypertension, heart attack, or stroke in a study of 5,740 participants of the cardiovascular cohort of the Malmö Diet and Cancer study; since other studies have afforded contradictory results, this allele is currently regarded as not associated with cardiovascular diseases (see Epoxyeicosatrienoic acid).[30] Bearers of this SNP in a Chinese Population had a higher risk of younger onset of type 2 diabetes and among a Chinese Han population had a higher risk of Alzheimer's disease.[29][unreliable source?] 3) CYP2C8*2 (11054A>T, rs11572103,[31][unreliable source?] Ile269Phe) and CYP2C8*4 (11041C>, rs1058930,[32][unreliable source?] variants have reduced arachidonic acid-metabolizing activity but have not been clearly associated with cardiovascular or other diseases.[28] 4) CYPC28*4 (3608C>T, rs1058930,[32][unreliable source?] Ile264Met) has reduced arachidonic acid metabolizing activity. It has not been associated with cardiovascular diseases but has a higher incidence in subjects with type II diabetes in a small sample of Caucasians in Germany.[33] 5) The CYP2C9*2 (3608C>T, rs1799853,[34][unreliable source?] Arg144Cys) variant has a 50% reduction in polyunsaturated fatty acid metabolizing activity compared to CYP2C9 wild type; carriers of it show no association with cardiovascular disease but exhibit poor metabolism of the anti-coagulating, blood-thinning agent, warfarin. These carriers are susceptible to the gastrointestinal bleeding side effects of warfarin and the NSAID cited above.[34][unreliable source?] 6 ) CYP2C9*3 (42624A>C, rs1057910,[35][unreliable source?] Iso359Leu) encodes an expoxygenase with reduced arachidonic acid metabolizing activity. This allele has not been directly associated with cardiovascular diseases but may be associated with the poor metabolism and therefore adverse reactions to warfarin, NSAID, sulfonylurea-containing oral hypoglycemic agents, and the anti-(epilepsy) drug, phenytoin.[35][unreliable source?] 7) CYP2C19*2 (19154G>A, rs4244285,[36][unreliable source?] Il264Met) and CYP2C19*3 (17948G>A, rs4986893,[37][unreliable source?] His212X) are loss-of-function null alleles; carriers of the CYP2C19*3 but not the CYP2C19*2 allele showed a reduced risk of developing essential hypertension in a large Korean population study.[38] Bearers of null alleles would be expected to be poor metabolizers of several drugs which are CYP2C19*2 or CYP2C19*3 substrates. This is particularly the case with Clopidogrel, a drug used to block platelet activation, blood clotting, and thereby heart attack, stroke, and peripheral artery occlusion in people at high risk of these events; CYP2C19 metabolizes clopidogrel to it active form. Consequently, patients with severe deficiencies in this CYP, i.e. bearers of CYP2C19*3 or CYP2C19*2 alleles, fail to gain protection from clopidogrel and have a higher risk of the cited cardiovascular events than clopidogrel-treated patients bearing wild type CYP2C19 alleles.[39] 8) CYPC19*17 (-800C>T, rs12248560, site[40][unreliable source?] upstream gene promoter site) causes overproduction of its epoxygenase and thereby the ultra fast metabolism of arachidonic acid. Bearers of this allele have not been associated with cardiovascular diseases but clearly show a decreased risk of developing breast cancer and endometriosis possible because their rapid metabolism of estrogen leads to lower estrogen levels and thereby a lower risk of these estrogen-fueled diseases.[40][unreliable source?][41][42] These bearers also a higher rate of metabolism of, and therefore reduced responsiveness to, certain proton pump inhibitor and antidepressant drugs.[40][unreliable source?]

Genetic polymorphism in Cytochrome P450 reductase

As indicated above, Cytochrome P450 reductase (POR) is responsible for regenerating the activity of CYPs including the epoxygenases. Several genetic variants of the human POR gene impact epoxygenase activity. For example, POR Missense mutations A287P[43] and R457H[44] lead to reductions in the activity of CYP2C19 and CYP2C9, respectively, whereas A503V[45] and Q153R[46] missense mutations lead to small increases in the activity of CYP2C9.[2] While these and other POR genetic variants have not yet been associated with epoxygenase-related disease, they contribute to the marked variability in the activity of the epoxygenases between individuals.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Spector, A. A.; Kim, H. Y. (2015). "Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1851 (4): 356–65. doi:10.1016/j.bbalip.2014.07.020. PMID 25093613. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Shahabi, P; Siest, G; Meyer, U. A.; Visvikis-Siest, S (2014). "Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders". Pharmacology & Therapeutics 144 (2): 134–61. doi:10.1016/j.pharmthera.2014.05.011. PMID 24882266. 
  3. ↑ 3.0 3.1 Barbosa-Sicard, E; Markovic, M; Honeck, H; Christ, B; Muller, D. N.; Schunck, W. H. (2005). "Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily". Biochemical and Biophysical Research Communications 329 (4): 1275–81. doi:10.1016/j.bbrc.2005.02.103. PMID 15766564. 
  4. ↑ Harris, T. R.; Hammock, B. D. (2013). "Soluble epoxide hydrolase: Gene structure, expression and deletion". Gene 526 (2): 61–74. doi:10.1016/j.gene.2013.05.008. PMID 23701967. 
  5. ↑ Hart, S. N.; Zhong, X. B. (2008). "P450 oxidoreductase: Genetic polymorphisms and implications for drug metabolism and toxicity". Expert Opinion on Drug Metabolism & Toxicology 4 (4): 439–52. doi:10.1517/17425255.4.4.439. PMID 18433346. 
  6. ↑ 6.0 6.1 Fer, M; Dréano, Y; Lucas, D; Corcos, L; Salaün, J. P.; Berthou, F; Amet, Y (2008). "Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450". Archives of Biochemistry and Biophysics 471 (2): 116–25. doi:10.1016/j.abb.2008.01.002. PMID 18206980. 
  7. ↑ 7.0 7.1 Westphal, C; Konkel, A; Schunck, W. H. (2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators 96 (1–4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID 21945326. 
  8. ↑ 8.0 8.1 8.2 Frömel, T; Kohlstedt, K; Popp, R; Yin, X; Awwad, K; Barbosa-Sicard, E; Thomas, A. C.; Lieberz, R et al. (2013). "Cytochrome P4502S1: A novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques". Basic Research in Cardiology 108 (1): 319. doi:10.1007/s00395-012-0319-8. PMID 23224081. 
  9. ↑ Bishop-Bailey, D; Thomson, S; Askari, A; Faulkner, A; Wheeler-Jones, C (2014). "Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism". Annual Review of Nutrition 34: 261–79. doi:10.1146/annurev-nutr-071813-105747. PMID 24819323. http://researchonline.rvc.ac.uk/id/eprint/9922/. 
  10. ↑ 10.0 10.1 10.2 10.3 Fleming, I (2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID 25244930. 
  11. ↑ 11.0 11.1 11.2 Yang, L; Mäki-Petäjä, K; Cheriyan, J; McEniery, C; Wilkinson, I. B. (2015). "The role of epoxyeicosatrienoic acids in the cardiovascular system". British Journal of Clinical Pharmacology 80 (1): 28–44. doi:10.1111/bcp.12603. PMID 25655310. 
  12. ↑ Draper, A. J.; Hammock, B. D. (2000). "Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase". Archives of Biochemistry and Biophysics 376 (1): 199–205. doi:10.1006/abbi.2000.1705. PMID 10729206. 
  13. ↑ Konkel, A; Schunck, W. H. (2011). "Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1814 (1): 210–22. doi:10.1016/j.bbapap.2010.09.009. PMID 20869469. 
  14. ↑ Moran, J. H.; Weise, R; Schnellmann, R. G.; Freeman, J. P.; Grant, D. F. (1997). "Cytotoxicity of linoleic acid diols to renal proximal tubular cells". Toxicology and Applied Pharmacology 146 (1): 53–9. doi:10.1006/taap.1997.8197. PMID 9299596. https://zenodo.org/record/1229968. 
  15. ↑ 15.0 15.1 Greene, J. F.; Hammock, B. D. (1999). "Toxicity of Linoleic Acid Metabolites". Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 4. Advances in Experimental Medicine and Biology. 469. pp. 471–7. doi:10.1007/978-1-4615-4793-8_69. ISBN 978-1-4613-7171-7. 
  16. ↑ Linhartová, I; Bumba, L; Mašín, J; Basler, M; Osička, R; Kamanová, J; Procházková, K; Adkins, I et al. (2010). "RTX proteins: A highly diverse family secreted by a common mechanism". FEMS Microbiology Reviews 34 (6): 1076–112. doi:10.1111/j.1574-6976.2010.00231.x. PMID 20528947. 
  17. ↑ Greene, J. F.; Newman, J. W.; Williamson, K. C.; Hammock, B. D. (2000). "Toxicity of epoxy fatty acids and related compounds to cells expressing human soluble epoxide hydrolase". Chemical Research in Toxicology 13 (4): 217–26. doi:10.1021/tx990162c. PMID 10775319. 
  18. ↑ Zheng, J; Plopper, C. G.; Lakritz, J; Storms, D. H.; Hammock, B. D. (2001). "Leukotoxin-diol: A putative toxic mediator involved in acute respiratory distress syndrome". American Journal of Respiratory Cell and Molecular Biology 25 (4): 434–8. doi:10.1165/ajrcmb.25.4.4104. PMID 11694448. 
  19. ↑ Edwards, L. M.; Lawler, N. G.; Nikolic, S. B.; Peters, J. M.; Horne, J; Wilson, R; Davies, N. W.; Sharman, J. E. (2012). "Metabolomics reveals increased isoleukotoxin diol (12,13-DHOME) in human plasma after acute Intralipid infusion". The Journal of Lipid Research 53 (9): 1979–86. doi:10.1194/jlr.P027706. PMID 22715155. 
  20. ↑ 20.0 20.1 "Cytochrome P450 Enzymes in the Bioactivation of Polyunsaturated Fatty Acids and Their Role in Cardiovascular Disease". Monooxygenase, Peroxidase and Peroxygenase Properties and Mechanisms of Cytochrome P450. Advances in Experimental Medicine and Biology. 851. 2015. pp. 151–87. doi:10.1007/978-3-319-16009-2_6. ISBN 978-3-319-16008-5. 
  21. ↑ Wagner, K; Inceoglu, B; Hammock, B. D. (2011). "Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception". Prostaglandins & Other Lipid Mediators 96 (1–4): 76–83. doi:10.1016/j.prostaglandins.2011.08.001. PMID 21854866. 
  22. ↑ Zhang, G; Kodani, S; Hammock, B. D. (2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research 53: 108–23. doi:10.1016/j.plipres.2013.11.003. PMID 24345640. 
  23. ↑ Yang, J; Solaimani, P; Dong, H; Hammock, B; Hankinson, O (2013). "Treatment of mice with 2,3,7,8-Tetrachlorodibenzo-p-dioxin markedly increases the levels of a number of cytochrome P450 metabolites of omega-3 polyunsaturated fatty acids in the liver and lung". The Journal of Toxicological Sciences 38 (6): 833–6. doi:10.2131/jts.38.833. PMID 24213002. 
  24. ↑ Holt, R. R.; Yim, S. J.; Shearer, G. C.; Hackman, R. M.; Djurica, D; Newman, J. W.; Shindel, A. W.; Keen, C. L. (2015). "Effects of short-term walnut consumption on human microvascular function and its relationship to plasma epoxide content". The Journal of Nutritional Biochemistry 26 (12): 1458–66. doi:10.1016/j.jnutbio.2015.07.012. PMID 26396054. 
  25. ↑ "Rs10509681 - SNPedia". http://www.snpedia.com/index.php/Rs10509681. 
  26. ↑ Tzveova, R; Naydenova, G; Yaneva, T; Dimitrov, G; Vandeva, S; Matrozova, Y; Pendicheva-Duhlenska, D; Popov, I et al. (2015). "Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients". Biochemical Genetics 53 (11–12): 319–33. doi:10.1007/s10528-015-9696-7. PMID 26404779. 
  27. ↑ Agúndez, J. A.; García-Martín, E; Martínez, C (2009). "Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?". Expert Opinion on Drug Metabolism & Toxicology 5 (6): 607–20. doi:10.1517/17425250902970998. PMID 19422321. 
  28. ↑ 28.0 28.1 Daily, E. B.; Aquilante, C. L. (2009). "Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies". Pharmacogenomics 10 (9): 1489–510. doi:10.2217/pgs.09.82. PMID 19761371. 
  29. ↑ 29.0 29.1 29.2 "Rs890293 - SNPedia". http://www.snpedia.com/index.php/Rs890293. 
  30. ↑ Fava, C; Montagnana, M; Almgren, P; Hedblad, B; Engström, G; Berglund, G; Minuz, P; Melander, O (2010). "The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes". Journal of Hypertension 28 (2): 294–9. doi:10.1097/HJH.0b013e328333097e. PMID 19851119. 
  31. ↑ "Rs11572103 - SNPedia". http://www.snpedia.com/index.php/Rs11572103. 
  32. ↑ 32.0 32.1 "Rs1058930 - SNPedia". http://www.snpedia.com/index.php/Rs1058930. 
  33. ↑ Weise, A; Prause, S; Eidens, M; Weber, M. M.; Kann, P. H.; Forst, T; Pfützner, A (2010). "Prevalence of CYP450 gene variations in patients with type 2 diabetes". Clinical Laboratory 56 (7–8): 311–8. PMID 20857895. 
  34. ↑ 34.0 34.1 "Rs1799853 - SNPedia". http://www.snpedia.com/index.php/Rs1799853. 
  35. ↑ 35.0 35.1 "Rs1057910 - SNPedia". http://www.snpedia.com/index.php/Rs1057910. 
  36. ↑ "Rs4244285 - SNPedia". http://www.snpedia.com/index.php/Rs4244285. 
  37. ↑ "Rs4986893 - SNPedia". http://www.snpedia.com/index.php/Rs4986893. 
  38. ↑ Shin, D. J.; Kwon, J; Park, A. R.; Bae, Y; Shin, E. S.; Park, S; Jang, Y (2012). "Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans". Yonsei Medical Journal 53 (6): 1113–9. doi:10.3349/ymj.2012.53.6.1113. PMID 23074110. 
  39. ↑ Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R. (2011). "Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions". Clinical Pharmacology & Therapeutics 89 (3): 455–9. doi:10.1038/clpt.2010.316. PMID 21270785. 
  40. ↑ 40.0 40.1 40.2 "Rs12248560 - SNPedia". http://www.snpedia.com/index.php/Rs12248560. 
  41. ↑ Justenhoven, C; Hamann, U; Pierl, C. B.; Baisch, C; Harth, V; Rabstein, S; Spickenheuer, A; Pesch, B et al. (2009). "CYP2C19*17 is associated with decreased breast cancer risk". Breast Cancer Research and Treatment 115 (2): 391–6. doi:10.1007/s10549-008-0076-4. PMID 18521743. https://hal.archives-ouvertes.fr/hal-00478236/file/PEER_stage2_10.1007%252Fs10549-008-0076-4.pdf. 
  42. ↑ Painter, J. N.; Nyholt, D. R.; Krause, L; Zhao, Z. Z.; Chapman, B; Zhang, C; Medland, S; Martin, N. G. et al. (2014). "Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis". Fertility and Sterility 102 (2): 496–502.e5. doi:10.1016/j.fertnstert.2014.04.015. PMID 24796765. 
  43. ↑ "Mutation overview page NTNG1 - p.A287P ( Substitution - Missense)". http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=215444. 
  44. ↑ "Mutation overview page ZNF439 - p.R457H ( Substitution - Missense)". http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=1581970. 
  45. ↑ "Rs1057868 - SNPedia". https://www.snpedia.com/index.php/Rs1057868. 
  46. ↑ "Mutation overview page SLC22A2 - p.Q153R ( Substitution - Missense)". http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=1075652. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Epoxygenase&oldid=3714387"